-
Sector Analysis
NewReconstruction Meshes Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033
Reconstruction Meshes Market Report Overview The Reconstruction Meshes market size was $2.38 billion in 2023. Factors such as the rising number of breast reconstruction procedures and the growing prevalence of Pelvic Organ Prolapse (POP) will drive the market growth at a CAGR of more than 1% from 2023 to 2033. Reconstruction Meshes Market Outlook 2023-2033 ($ Billion) Buy the Full Report for More Insights on the Reconstruction Meshes Market Forecast, Download a Free Sample Report The Reconstruction Meshes market research...
-
Sector Analysis
NewNew Drug Approvals and Their Contract Manufacture – 2024 Edition
This report is the 14th edition of our long-running analysis of the CMO industry, using the FDA's NDA approvals as the primary indicator of performance. New Drug Approvals and Their Contract Manufacture (formerly called "CMO Scorecard") is critical for benchmarking the performance of the contract manufacturing organization (CMO) industry and the relative performance of major CMOs. This year's edition includes a discussion of how inflation and increasing global conflict has impacted pharma manufacturers.
-
Sector Analysis
NewTranscatheter Pulmonary Valve Replacement (TPVR) Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033
The Transcatheter Pulmonary Valve Replacement (TPVR) Market Report Overview The Transcatheter Pulmonary Valve Replacement (TPVR) market size was $44.6 million in 2023 and will drive the market growth at a CAGR of more than 8% from 2023 to 2033. Transcatheter heart valves are synthetic valves made from biological tissues surrounded by a steel, cobalt-chromium, or nitinol stent. There are two types of transcatheter heart valves: balloon expandable and self-expandable. One Transcatheter Heart Valve is referred to as a unit. TPVR...
-
Product Insights
NewNet Present Value Model: Theriva Biologics Inc’s Ribaxamase
Empower your strategies with our Net Present Value Model: Theriva Biologics Inc's Ribaxamase report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Innovent Biologics Inc’s Parsaclisib
Empower your strategies with our Net Present Value Model: Innovent Biologics Inc's Parsaclisib report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Theriva Biologics Inc’s SYN-020
Empower your strategies with our Net Present Value Model: Theriva Biologics Inc's SYN-020 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: HCW Biologics Inc’s HCW-9218
Empower your strategies with our Net Present Value Model: HCW Biologics Inc's HCW-9218 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Innovent Biologics Inc’s IBI-188
Empower your strategies with our Net Present Value Model: Innovent Biologics Inc's IBI-188 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Likelihood of Approval Analysis for Anxiety Disorders
Overview How likely is it that the drugs in Anxiety Disorders will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anxiety Disorders Overview Anxiety disorders are a group of mental health conditions...